Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use

T Matsushima, S Akira, Shigeo Akira, H Asakura, Hirofumi Asakura, Toshiyuki Takeshita, T Takeshita
Clinical and experimental obstetrics & gynecology · 2017 · vol. 44(1) , pp. 143–145 · doi:10.12891/ceog3214.2017 · PMID:29714885 · W3024292692
article OA: bronze CC0 ⤵ 7 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

The authors report a case of cerebral venous and sinus thrombosis (CVST) in a patient receiving a low-dose estrogen-progestin combination (oral contraceptives, OCs) for uterine adenomyosis. She was switched to gonadotropin-releasing hormone agonist (GnRHa) draw-back therapy, which was successfully administered long-term. CASE: The patient was a 38-year-old nulligravida with a history of smoking. She presented to this hospital with dysmenorrhea and postmenstrual lower abdominal pain. Adenomyosis was diagnosed using ultrasound and magnetic resonance imaging. She was instructed to stop smoking and was administered low-dose OCs. CVST occurred 18 months later. OC therapy was halted, and only antiplatelet therapy was administered. After six months, her chief complaint symptoms intensified, therefore GnRHa draw-back therapy was administered after obtaining informed consent. No uterine enlargement was observed, and the abdominal pain resolved. During 2.5 years of therapy, her bone density levels remained within normal limits. CVST did not recur and no other thromboses were observed.

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

MeSH descriptors

Adenomyosis Contraceptives, Oral, Hormonal Fertility Agents, Female Leuprolide Sinus Thrombosis, Intracranial Adenomyosis Adult Contraceptives, Oral, Hormonal Female Fertility Agents, Female Humans Leuprolide Sinus Thrombosis, Intracranial

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Cited by (7)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:37.704673+00:00
License: CC0 · commercial use OK